MedTrace Logo

COMparison Between All immunoTherapies for Multiple Sclerosis.

NCT03193866 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3526

Last updated 2025-04-20

Study results available
· View outcomes & findings →

Summary

The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based structured prospective follow-up cohort of Relapsing-Remitting Multiple Sclerosis (RRMS) patients. The study will include both treatment naïve patients starting their first DMT and patients switching from a previous first line DMT (escalation/second-line).

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Rituximab

Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis

Sponsors & Collaborators

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • Kaiser Foundation Research Institute

    collaborator OTHER

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Fredrik Piehl, MD, PhD · Karolinska Institutet

  • Anders Svenningsson, MD, PhD · Karolinska Institutet

  • Anna Fogdell-Hahn, PhD · Karolinska Institutet

  • Ingrid Kockum, PhD · Karolinska Institutet

  • Thomas Frisell, PhD · Karolinska Institutet

  • Annette Langer-Gould, MD, PhD · Kaiser Permanent Southern California, Los Angeles, USA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-02
Primary Completion
2022-03-31
Completion
2022-03-31
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193866 on ClinicalTrials.gov